$KPTI What is the possibility of this??? I would like to know if Karyopharm management is stepping up efforts into the development of verdinexor or is this a totally different application? This is dated 2016 It is expected that these studies will serve as important stepping stones for future clinical evaluations of verdinexor for its anti-influenza indication in human. Further, other human pathogenic viruses have also been reported to co-opt the host’s XPO1 pathway for nuclear exit, including the herpes simplex virus type-1 virus (HSV-1), human cytomegalovirus (HCMV), and the severe acute respiratory syndrome coronavirus (SARS-CoV) [24–26]. Thus, it is likely that verdinexor can also potentially inhibit replication of these viruses serving as a broad-spectrum antiviral.